Piper Jaffray Companies reissued their hold rating on shares of Axovant Sciences Ltd (NYSE:AXON) in a research note issued to investors on Friday morning.

A number of other analysts have also issued reports on AXON. ValuEngine lowered Axovant Sciences from a hold rating to a sell rating in a report on Tuesday, September 26th. HC Wainwright reaffirmed a buy rating and issued a $11.00 target price on shares of Axovant Sciences in a report on Wednesday, September 27th. Jefferies Group LLC reaffirmed a buy rating and issued a $12.00 target price on shares of Axovant Sciences in a report on Wednesday, September 27th. Chardan Capital reaffirmed a sell rating and issued a $3.00 target price on shares of Axovant Sciences in a report on Friday, November 3rd. Finally, BidaskClub lowered Axovant Sciences from a hold rating to a sell rating in a report on Saturday, August 19th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the stock. Axovant Sciences currently has an average rating of Hold and a consensus price target of $14.13.

Shares of Axovant Sciences (AXON) opened at $5.34 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.01 and a quick ratio of 6.01. Axovant Sciences has a fifty-two week low of $4.60 and a fifty-two week high of $27.98.

Axovant Sciences (NYSE:AXON) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12).

TRADEMARK VIOLATION WARNING: “Axovant Sciences’ (AXON) “Hold” Rating Reiterated at Piper Jaffray Companies” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/axovant-sciences-axon-hold-rating-reiterated-at-piper-jaffray-companies/1698994.html.

Several institutional investors have recently bought and sold shares of AXON. Oppenheimer & Co. Inc. bought a new position in shares of Axovant Sciences during the 3rd quarter worth approximately $101,000. Bank of America Corp DE lifted its position in shares of Axovant Sciences by 38.9% during the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares during the period. Legal & General Group Plc lifted its position in shares of Axovant Sciences by 20.2% during the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after buying an additional 1,168 shares during the period. American International Group Inc. lifted its position in shares of Axovant Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in shares of Axovant Sciences by 38.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after buying an additional 2,789 shares during the period.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.